Rossari Biotech Q4 Net Profit Up 34% YoY

Rossari Biotech announced Q4 FY26 results with revenue up 18% YoY to Rs. 684.9 crore and PAT up 34% to Rs. 46.0 crore.
EBITDA increased 11% to Rs. 77.3 crore, while margin was 11.3% vs 12.0% last year; FY26 revenue grew 15% to Rs. 2,396.4 crore.
The company commissioned 15,000 MTPA ethoxylation capacity at Dahej, taking total to 66,000 MTPA, and recommended a dividend of Re. 0.50 per share.
Key developments include appointment of an independent director and setup of a new R&D facility in Navi Mumbai.